Form 4: Summit Therapeutics Co-CEO Robert Duggan Reports Changes in Beneficial Ownership Following Marriage

Summit Therapeutics Co-Chief Executive Officer Robert Duggan reports changes in his beneficial ownership of company stock and options following his recent marriage.

Summary

• Robert Duggan, Co-Chief Executive Officer of Summit Therapeutics, filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
• The changes are primarily due to his marriage on December 18, 2024, which resulted in him acquiring beneficial ownership of securities previously held by his spouse.
• Duggan now indirectly owns 551,695,096 shares of common stock, 31,000 shares through his spouse, 10,199,776 shares through the Shaun Zanganeh Irrevocable Trust, 25,457,666 shares through the Mahkam Zanganeh Revocable Trust, and 50,000 shares through an immediate family member of his spouse.
• He also acquired 10,724 stock options on January 2, 2025, with an exercise price of $18.35, which vest quarterly.
• Additionally, he indirectly owns various stock options through his spouse, including options granted in 2020, 2021, and 2023, some of which are fully vested and others that are subject to performance conditions.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing changes in ownership due to a personal event, not a business transaction. There is no positive or negative sentiment associated with the filing itself.

Positives

• The acquisition of stock and options through marriage indicates a potential alignment of interests between the Co-CEO and his spouse.
• The newly granted options to the Co-CEO vest quarterly, which may incentivize continued service as a non-salaried director.

Negatives

• The report primarily reflects changes due to marriage and does not indicate any new purchases or sales of stock by the Co-CEO.
• The Co-CEO disclaims beneficial ownership of the securities held by his spouse, except for his pecuniary interest, which may limit his direct control over these assets.

Risks

• The performance-based stock options held by the spouse are subject to the satisfaction of market capitalization and revenue targets, which may not be achieved.
• The vesting of the Co-CEO's options is contingent on him remaining a non-salaried director, which could be a risk if his role changes.

Future Outlook

The document does not contain any forward-looking statements or guidance.

Management Comments

• The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
• The inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

Industry Context

Form 4 filings are a standard part of regulatory compliance for company insiders, providing transparency into their transactions and holdings. This filing is specific to changes in beneficial ownership due to a personal event (marriage) rather than a market transaction.

Comparison to Industry Standards

• Form 4 filings are a common practice across all publicly traded companies in the US, and this filing is consistent with the requirements of the SEC.
• The reporting of stock options and their vesting schedules is standard practice for executive compensation disclosures.
• The disclaimer of beneficial ownership for securities held by a spouse is also a common practice to avoid unnecessary attribution of ownership.

Stakeholder Impact

• The filing provides transparency to shareholders regarding the Co-CEO's ownership stake in the company.
• The vesting of options may incentivize the Co-CEO to continue his service as a non-salaried director.

Key Dates

Keywords

beneficial ownership, stock options, Form 4, Summit Therapeutics, Robert Duggan, insider trading, equity securities, vesting, performance options